UNASSIGNED: 160 Background: In @entity1 with BRPC(M0) after local tx, the most important prognostic factor is probably the PSADT (high risk < 3, intermediate risk 3-8.9, low risk >= 9.0 months). Pre-clinical and clinical studies in several @entity5 types have shown that commonly prescribed medications may inhibit @entity5 growth. The effect of commonly prescribed medications on PSADT in pts with BRPC(M0) is poorly defined. We aimed to study the effect of commonly prescribed medications on PSADT in pts with BRPC (M0) after local tx. METHODS: We reviewed the records of 156 BRPC(M0) pts enrolled in 1 prospective (Keizman, CCR 2010) and two retrospective (Keizman, prostate 2012; Mermershtain, EMUC 2011) studies, in 2 centers across 2 countries. The effect of clinicopathologic factors and the use of @entity6817 , @entity117 , and angiotensin system inhibitors (ASIs; ACE-I and ARBs) on initial PSADT (from the time of first PSA relapse to the initiation of any systemic tx) was analyzed using the Mann-Whitney or Kruskal-Wallis tests and regression analyses. RESULTS: In the whole @entity1 cohort (n=156), median age was 62, prior local tx consisted of radical prostatectomy in128 pts and EBRT in 28, and median PSADT was 6.7 months (mos). Median PSADT in ASIs users (n=48) vs non users (n=108) was 7.85 vs 5.6 mos (p=0.011). In multivariate analysis, the use of ASIs and Gleason score were associated with median PSADT. The use of statins (n=58) or @entity117 (n=72), primary tx modality, and time from primary tx to PSA relapse had no significant effect on median PSADT. PSADT risk grouping in ASIs users vs non users was low 48% vs 27%, intermediate 42% vs 49%, and high 10% vs 24% (p=0.02). In multivariate analysis, the use of ASIs, Gleason score, and prior ADT were associated with PSADT risk grouping. The use of statins or @entity117 , primary tx modality, and time from primary tx to PSA relapse had no significant effect on PSADT risk grouping. CONCLUSIONS: The use of ASIs, Gleason score, and prior ADT may be associated with PSADT (median and risk grouping) of pts with BRPC (M0) after local tx. This should be investigated prospectively, and if validated, applied in clinical practice and clinical trials.

Influence of concurrent medications on PSA doubling time (PSADT) in XXXX (pts) with nonmetastatic biochemically relapsed prostate cancer (BRPC M0) after local therapy (tx).

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity6817 :: ('D019821', 'Chemical') :: ['statins'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']
@entity1 :: (9606,Species) :: ['patients']
